05.13.24
ERS Genomics Ltd., a CRISPR licensing company, has appointed John E. Milad as CEO, effective immediately. John brings more than 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology sectors.
As CEO of Quanta Dialysis Technologies for nearly a decade, John led the development and commercial launch of an award-winning portable haemodialysis system designed to transform the delivery of kidney care to patients. He drove market entry into the UK and U.S., while raising $245 million private funding round and building an extensive intellectual property estate of over 40 patent families. Prior to this, he served as CFO of Nitec Pharma, where he headed up finance and business development activities, raising a pivotal funding round and securing a licensing partner to enable the company’s transition from clinical development to commercialization.
John also has significant experience as a venture investor, with previous roles as Partner and co-Head of Healthcare Ventures at Downing LLP and Investment Director at NBGI Ventures, as well as positions at Atlas Venture and Kirkland Investors. Successful exited investments include Symetis, ACT/Epix, BoneSupport and WebMD.
John E Milad, CEO, ERS Genomics, said, “Gene editing using CRISPR/Cas9 continues to gain momentum across a wide variety of applications, playing a vital role in ushering in a golden age for medical innovation and synthetic biology. ERS' mission is to broaden the secure use of CRISPR/Cas9 by enhancing and expanding accessibility, helping to drive the technology to its full potential. I am delighted to join ERS, with their decade of experience as a respected provider of CRISPR/Cas9 licensing and look forward to working with the team to continue making CRISPR gene-editing available to the world.”
As CEO of Quanta Dialysis Technologies for nearly a decade, John led the development and commercial launch of an award-winning portable haemodialysis system designed to transform the delivery of kidney care to patients. He drove market entry into the UK and U.S., while raising $245 million private funding round and building an extensive intellectual property estate of over 40 patent families. Prior to this, he served as CFO of Nitec Pharma, where he headed up finance and business development activities, raising a pivotal funding round and securing a licensing partner to enable the company’s transition from clinical development to commercialization.
John also has significant experience as a venture investor, with previous roles as Partner and co-Head of Healthcare Ventures at Downing LLP and Investment Director at NBGI Ventures, as well as positions at Atlas Venture and Kirkland Investors. Successful exited investments include Symetis, ACT/Epix, BoneSupport and WebMD.
John E Milad, CEO, ERS Genomics, said, “Gene editing using CRISPR/Cas9 continues to gain momentum across a wide variety of applications, playing a vital role in ushering in a golden age for medical innovation and synthetic biology. ERS' mission is to broaden the secure use of CRISPR/Cas9 by enhancing and expanding accessibility, helping to drive the technology to its full potential. I am delighted to join ERS, with their decade of experience as a respected provider of CRISPR/Cas9 licensing and look forward to working with the team to continue making CRISPR gene-editing available to the world.”